101 related articles for article (PubMed ID: 1823391)
1. Total body bone mineral and tartrate-resistant acid phosphatase levels in type I and III osteogenesis imperfecta.
Rico H; Revilla M; Iritia M; Arribas I; Fernando Villa L
Miner Electrolyte Metab; 1991; 17(6):396-8. PubMed ID: 1823391
[TBL] [Abstract][Full Text] [Related]
2. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
3. [Biological profile and value of determination of tartrate-resistant acid phosphatase in children].
Rico Lenza H; Revilla Amores M; Iritia Bartolomé M; Arribas Gómez I
An Esp Pediatr; 1991 Apr; 34(4):289-91. PubMed ID: 2069278
[TBL] [Abstract][Full Text] [Related]
4. [Biological profile of tartrate-resistant acid phosphatase as a marker of bone resorption].
Rico H; Iritia M; Arribas I; Revilla M
Rev Esp Fisiol; 1990 Dec; 46(4):379-83. PubMed ID: 2099535
[TBL] [Abstract][Full Text] [Related]
5. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
[TBL] [Abstract][Full Text] [Related]
6. Enzyme histochemical localisation of alkaline phosphatase activity in osteogenesis imperfecta bone and growth plate: a preliminary study.
Sarathchandra P; Cassella JP; Ali SY
Micron; 2005; 36(7-8):715-20. PubMed ID: 16182549
[TBL] [Abstract][Full Text] [Related]
7. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.
Glorieux FH; Ward LM; Rauch F; Lalic L; Roughley PJ; Travers R
J Bone Miner Res; 2002 Jan; 17(1):30-8. PubMed ID: 11771667
[TBL] [Abstract][Full Text] [Related]
8. Osteogenesis imperfecta: changes in noncollagenous proteins in bone.
Vetter U; Fisher LW; Mintz KP; Kopp JB; Tuross N; Termine JD; Robey PG
J Bone Miner Res; 1991 May; 6(5):501-5. PubMed ID: 2068957
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
10. [Bone mineral content in osteogenesis imperfecta].
Rajtár M; László A; Beviz J; Bossányi A; Almási L; Csernay L
Orv Hetil; 1996 Jul; 137(28):1519-23. PubMed ID: 8757074
[TBL] [Abstract][Full Text] [Related]
11. In vitro expression of osteoblastic markers in cells isolated from normal fetal and postnatal human bone and from bone of patients with osteogenesis imperfecta.
Mörike M; Schulz M; Brenner RE; Bushart GB; Teller WM; Vetter U
J Cell Physiol; 1993 Dec; 157(3):439-44. PubMed ID: 8253854
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers in patients with osteogenesis imperfecta.
Braga V; Gatti D; Rossini M; Colapietro F; Battaglia E; Viapiana O; Adami S
Bone; 2004 Jun; 34(6):1013-6. PubMed ID: 15193547
[TBL] [Abstract][Full Text] [Related]
13. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
Saganelidze KhZ
Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
[TBL] [Abstract][Full Text] [Related]
14. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
15. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
16. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
17. Do patients with osteogenesis imperfecta need individualized nutritional support?
Chagas CE; Roque JP; Santarosa Emo Peters B; Lazaretti-Castro M; Martini LA
Nutrition; 2012 Feb; 28(2):138-42. PubMed ID: 21795023
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
19. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
20. Potential of densitometric measurement in selected pediatric subject.
Lorenc RS; Matusik H; Olszaniecka M; Lebiedowski M
Acta Univ Carol Med (Praha); 1994; 40(1-4):23-8. PubMed ID: 9355667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
